September 15, 2024 – XinKailian Biotechnology, a leading player in the nutraceutical industry, proudly announces the launch of its GMP-certified product Ubiquinol (Reduced Coenzyme Q10), which comes with full independent intellectual property rights and comprehensive system certification under USP43 standards. Backed by a comprehensive Freedom to Operate (FTO) analysis, this product addresses the industry's key concerns regarding patent risks and provides customers with confidence and security. It will be publicly unveiled for the first time at Vitafoods Asia 2024.
Comprehensive Freedom to Operate analysis alleviates patent concerns
With growing market concerns about potential patent infringement lawsuits, particularly from Kaneka, XinKailian Biotechnology has conducted a thorough FTO analysis. Of 598 patents reviewed, 62 were deemed relevant. Of these, 16 were rated low risk and 46 were rated no risk. No high or medium risk patents were identified. This rigorous assessment, conducted by Unitalen Attorneys At Law and reviewed by U.S. attorney Kilpatrick Townsend & Stockton LLP, ensures that companies can confidently switch to XinKailian's ubiquinol without the risk of legal consequences.
Commitment to quality through advanced production techniques
XinKailian's Ubiquinol is manufactured using modern processes that ensure high purity and potency. The CoQ10 raw material is obtained through natural fermentation processes, ensuring premium quality. In addition, mild reaction conditions and ultra-low temperature processing are used to preserve the biological activity of Ubiquinol and improve both absorption and stability. This commitment to innovation reflects XinKailian's dedication to quality in the highly competitive nutraceutical market.
Global market readiness with GMP-certified ubiquinol
XinKailian Biotechnology is prepared to meet global demand with fully functional facilities that comply with Good Manufacturing Practices (GMP). The company offers products at competitive prices that enable companies to maintain the highest quality standards while improving their profit margins.
Meet We at Vitafoods Asia 2024
XinKailian Biotechnology will showcase its new GMP-certified Ubiquinol at Vitafoods Asia 2024 from September 18 to 20 at the Queen Sirikit National Convention Center in Bangkok. Visitors are welcome to visit booth S10 at the Yili Chuanning Biotech booth. As a partner of Kelun Group, one of China's top three pharmaceutical manufacturers, XinKailian is excited to showcase this innovative product and its entry into the nutraceuticals market.
About XinKailian Biotechnology
XinKailian Biotechnology specializes in the production of high-quality Ubiquinol, a key ingredient for cardiovascular health, neuroprotection and anti-aging applications. The company's commitment to GMP certification and USP43 compliance ensures that its products meet the highest industry standards for safety, efficacy and quality.
For more information, please visit XinKailian Biotechnology at Vitafoods Asia 2024 or contact us directly.
Please contact:
E-mail: [email protected]
Mobile: +81-80-1551-1259
General inquiries: Email: [email protected]
Phone: +86 18058818015
website: www.mfad.com.cn
About the Author
